A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies.

Terakura, S; Atsuta, Y; Sawa, M; Ohashi, H; Kato, T; Nishiwaki, S; Imahashi, N; Yasuda, T; Murata, M; Miyamura, K; Suzuki, R; Naoe, T; Ito, T; Morishita, Y

Terakura, S; Atsuta, Y; Sawa, M; Ohashi, H; Kato, T; Nishiwaki, S; Imahashi, N; Yasuda, T; Murata, M; Miyamura, K; Suzuki, R; Naoe, T; Ito, T; Morishita, Y.

Affiliation

Terakura S; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Japan. tseit@med.nagoya-u.ac.jp

Ann Oncol ; 22(8): 1865-71, 2011 Aug.

Article in En | MEDLINE | ID: mdl-21289367

Subject(s)

Bone Marrow Transplantation; Chimerism/drug effects; Hematologic Neoplasms/surgery; Melphalan/administration & dosage; Myeloablative Agonists/administration & dosage; Transplantation Conditioning/methods; Vidarabine/analogs & derivatives; Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; T-Lymphocytes/drug effects; Tissue Donors; Transplantation, Homologous; Vidarabine/administration & dosage

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Vidarabine / Bone Marrow Transplantation / Hematologic Neoplasms / Transplantation Conditioning / Myeloablative Agonists / Chimerism / Melphalan Type of study: Diagnostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Year: 2011 Type: Article

Fulltext

XML

PubMed Links

Search on Google